Cortical inhibition by Retigabine. Assesment by transcranial magnetic stimulation in epilepsy patients.

Cortical inhibition by Retigabine. Assesment by transcranial magnetic stimulation in epilepsy patients. - Corticale inhibition by Retigabine.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37062

Enrollment

Registered

2013-03-12

Start date

2013-02-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

focal epilepsy partial epilepsy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Partial onset epilepsy (with or without secondary generalization) that is not sufficiently controlled by the current medication. There is an indication to initiate adjuvant treatment with Retigabine. The decision to start Retigabine is in taken by the patients neurologist. After that decision the patient may participate in the current study.

Exclusion criteria

Exclusion criteria: - implanted electronic or magnetic devices (safety ) - clinical or radiological evidence of major structural abnormality of the motor cortex or the pyramidal tract

Design outcomes

Primary

Measure	Time frame
Primairy outcome is the change of intracortical facilitation and silent period by 900 mg/day (or maximum dose) Retigabine.	—

Secondary

Measure	Time frame
Relation between long interval cortical inhibition and clinical effect (>50% seizure reduction).	—

Countries

Netherlands

Outcome results